CD274 and non-small cell lung carcinoma: The use of programmed cell death‐1 (PD‐1) inhibitors or programmed death‐ligand 1 (PD‐L1) inhibitors is successful in achieving improved prognosis of advanced NSCLC patients either in first‐ or second‐line settings in clinical trials.5, 6, 7, 8, 9